Mark Kieran

MD, PhD, is Director of Pediatric Medical Neuro-Oncology

BIO

Mark W. Kieran, MD, PhD, is Director of Pediatric Medical Neuro-Oncology at Dana-Farber Cancer Institute and Children’s Hospital Boston. He is also an Associate Professor of Pediatrics at Harvard Medical School. Dr. Kieran’s primary research interest is the development of new therapies for children with brain tumors. His laboratory has tested many new biologic and anti-angiogenic agents and many of these are currently being tested in patients. Dr Kieran is the Principal  Investigator at Dana-Farber Cancer Institute for the Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC); he is a co-chair of the malignant glioma section of the Children’s Oncology Group (COG) and is the chair of the glioma section of the Department of Defense (DOD) NF1 Consortium.

 

Dr. Kieran is a member of the Society for Neuro-Oncology, the Society of Pediatric Research, and the American Society for Clinical Oncology. He is the editor in chief of Clinical Oncology in Adolescent and Young Adult and serves on the Editorial Board of Neuro-Oncology. Dr. Kieran is an ad hoc reviewer for many journals including the New England Journal of MedicinePediatric Blood and CancerCancer Research, and the Journal of Pediatric Hematology/Oncology. He is a recipient of many awards including the Nick Palmer Lecture Award from the International Symposium on Pediatric Neuro-Oncology and presents lectures both at home and abroad, most recently at the Children’s Cancer Institute of Egypt and the Beijing Children’s Hospital.

 

Dr. Kieran received his PhD in 1983 from the University of Alberta, Edmonton, Canada, and his MD in 1986 from the University of Calgary. He completed postgraduate training in molecular biology at the Pasteur Institute in Paris. After a pediatric residency at McGill University in Montreal, he received postdoctoral education at Children’s Hospital Boston. Dr. Kieran became Director of Pediatric Medical Neuro-Oncology at Dana-Farber in 1999.